MarketCap
Facebook
X
TelegramAnnual report 2024
added 02-21-2026
Can-Fite BioPharma Ltd. Total Assets 2011-2026 | CANF
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Can-Fite BioPharma Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.12 M | 9.99 M | 9.28 M | 20.3 M | 9.52 M | 8.17 M | 7.95 M | 7.83 M | 10.2 M | 17.6 M | 10.2 M | 6.63 M | 1.64 M | 4.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 20.3 M | 1.64 M | 9.52 M |
Quarterly Total Assets Can-Fite BioPharma Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 20.3 M | - | 9.68 M | - | 9.52 M | - | 12.8 M | - | 8.17 M | - | - | - | 7.95 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 20.3 M | 7.95 M | 11.4 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B |  USA |
 |
Apellis Pharmaceuticals
APLS
|
1.08 B | $ 20.22 | -2.32 % | $ 2.55 B | USA |
 |
Aptorum Group Limited
APM
|
16.1 M | $ 0.82 | -3.48 % | $ 4.47 M | China |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M |  France |
 |
Axsome Therapeutics
AXSM
|
690 M | $ 164.71 | -1.01 % | $ 8.19 B | USA |
 |
AbCellera Biologics
ABCL
|
1.36 B | $ 3.73 | -2.49 % | $ 1.11 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
3.11 B | $ 8.5 | -2.63 % | $ 1.39 B | Britain |
 |
Catalyst Pharmaceuticals
CPRX
|
1.1 B | $ 23.88 | - | $ 2.92 B | USA |
 |
Corvus Pharmaceuticals
CRVS
|
45.6 M | $ 18.08 | 1.06 % | $ 868 M | USA |
 |
Adverum Biotechnologies
ADVM
|
180 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
Certara
CERT
|
1.56 B | $ 7.19 | 1.93 % | $ 1.15 B | USA |
 |
Eton Pharmaceuticals
ETON
|
31.7 M | $ 17.72 | -2.37 % | $ 454 M | USA |
 |
Exelixis
EXEL
|
2.84 B | $ 40.99 | -0.1 % | $ 11.1 B | USA |
 |
ARCA biopharma
ABIO
|
396 M | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
11.6 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
287 M | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | USA |
 |
Galapagos NV
GLPG
|
4.14 B | $ 33.13 | -2.82 % | $ 2.69 B |  Belgium |
 |
Greenwich LifeSciences
GLSI
|
4.09 M | $ 27.7 | 1.12 % | $ 361 M | USA |
 |
Genmab A/S
GMAB
|
21.1 B | $ 27.67 | -6.69 % | $ 17.7 B |  Danmark |
 |
Capricor Therapeutics
CAPR
|
58.7 M | $ 26.04 | -3.07 % | $ 697 M | USA |
 |
Acasti Pharma
ACST
|
72 M | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
149 M | $ 0.99 | -2.92 % | $ 72.7 M | USA |
 |
Halozyme Therapeutics
HALO
|
2.53 B | $ 69.39 | -0.67 % | $ 8.32 B | USA |
 |
Harmony Biosciences Holdings
HRMY
|
1.27 B | $ 28.56 | -1.19 % | $ 1.64 B | USA |
 |
ImmuCell Corporation
ICCC
|
45.1 M | $ 6.3 | -3.67 % | $ 51.5 M | USA |
 |
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
35.1 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
12 M | - | -10.17 % | $ 12.2 K | USA |
 |
Immuron Limited
IMRN
|
24.9 M | $ 0.75 | -0.69 % | $ 6.43 M |  Australia |
 |
Immunic
IMUX
|
24.1 M | $ 1.1 | 3.3 % | $ 171 M | USA |
 |
Immunovant
IMVT
|
776 M | $ 26.99 | -2.74 % | $ 4.09 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | USA |
 |
Inhibrx
INBX
|
308 M | $ 75.96 | -1.97 % | $ 3.58 B | USA |
 |
InMed Pharmaceuticals
INM
|
14.1 M | $ 0.75 | -8.49 % | $ 1.84 M | Canada |
 |
INmune Bio
INMB
|
57 M | $ 1.41 | 6.07 % | $ 25.4 M | USA |
 |
Insmed Incorporated
INSM
|
2.26 B | $ 146.89 | 0.39 % | $ 29.2 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
47.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
314 M | $ 3.19 | -4.49 % | $ 1.14 M | USA |
 |
Innate Pharma S.A.
IPHA
|
111 M | $ 1.63 | -1.21 % | $ 235 M | France |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M |  Israel |
 |
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
1.3 B | $ 29.11 | -0.31 % | $ 1.69 B | USA |